Z. Abdel-razzak, P. Loyer, A. Fautrel, J. C. Gautier, L. Corcos et al., Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture, Mol. Pharmacol, vol.44, pp.707-715, 1993.

B. B. Aggarwal, Signalling pathways of the TNF superfamily: a double-edged sword, Nat. Rev. Immunol, vol.3, p.745, 2003.

A. E. Aitken and E. T. Morgan, Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P4502C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes, Drug Metab. Dispos. Biol. Fate Chem, vol.35, pp.1687-1693, 2007.

A. E. Aitken, T. A. Richardson, and E. T. Morgan, Regulation of Drug-Metabolizing Enzymes and Transporters in Inflammation, Annu. Rev. Pharmacol. Toxicol, vol.46, pp.123-149, 2006.

S. Akira, S. Uematsu, and O. Takeuchi, Pathogen Recognition and Innate Immunity, Cell, vol.124, pp.783-801, 2006.

H. K. Al-ali, M. Griesshammer, P. Le-coutre, C. F. Waller, A. M. Liberati et al., Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial, Haematologica, vol.101, pp.1065-1073, 2016.

S. Al-fayoumi, T. Hashiguchi, Y. Shirakata, J. Mascarenhas, and J. W. Singer, Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis, J. Exp. Pharmacol, vol.10, pp.9-17, 2018.

C. Aninat, P. Seguin, P. Descheemaeker, F. Morel, Y. Malledant et al., Catecholamines induce an inflammatory response in human hepatocytes, Crit. Care Med, vol.36, pp.848-854, 2008.

M. S. Anwer and B. Stieger, Sodium-dependent bile salt transporters of the SCL10A Transporter Family: More than solute transporters, Pflugers Arch, p.466, 2014.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia, 2016.

S. Banerjee, A. Biehl, M. Gadina, S. Hasni, and D. M. Schwartz, JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects, vol.77, pp.521-546, 2017.

M. V. Barabanshikova, I. N. Zubarovsky, V. M. Savrasov, A. J. Korolkov, V. V. Baykov et al., Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation, Hematol. Oncol. Stem Cell Ther, 2019.

N. Bartalucci, L. Tozzi, C. Bogani, S. Martinelli, G. Rotunno et al., Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms, J. Cell. Mol. Med, vol.17, pp.1385-1396, 2013.

S. K. Biswas, M. Chittezhath, I. N. Shalova, and J. Lim, Macrophage polarization and plasticity in health and disease, Immunol. Res, vol.53, pp.11-24, 2012.

S. Black, I. Kushner, and D. Samols, C-reactive Protein, J. Biol. Chem, vol.279, pp.48487-48490, 2004.

D. Braig, T. L. Nero, H. Koch, B. Kaiser, X. Wang et al., Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites, Nat. Commun, vol.8, 2017.

D. Brenner, H. Blaser, and T. W. Mak, Regulation of tumour necrosis factor signalling: live or let die, Nat. Rev. Immunol, vol.15, pp.362-374, 2015.

N. Von-bubnoff, G. Ihorst, O. Grishina, N. Röthling, H. Bertz et al., Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628), 2018.

P. J. Campbell and A. R. Green, The Myeloproliferative Disorders, N. Engl. J. Med, vol.355, pp.2452-2466, 2006.

M. Chen, J. Liu, W. Yang, L. , and W. , Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling, 2017.

M. Chen, B. Pockaj, M. Andreozzi, M. T. Barrett, S. Krishna et al., JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer, Clin. Breast Cancer, vol.18, pp.1205-1215, 2018.

M. L. Choong, C. Pecquet, V. Pendharkar, C. C. Diaconu, J. W. Yong et al., Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors, J. Cell. Mol. Med, vol.17, pp.1397-1409, 2013.

B. Clarivet, P. Robin, Y. M. Pers, R. Ferreira, J. Lebrun et al., Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein, Eur. J. Clin. Pharmacol, vol.72, pp.1413-1414, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834388

P. Cohen and S. Strickson, The role of hybrid ubiquitin chains in the MyD88 and other innate immune signalling pathways, Cell Death Differ, vol.24, pp.1153-1159, 2017.

D. E. Coutant and S. D. Hall, Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance, J. Clin. Pharmacol, vol.58, pp.849-863, 2018.

M. Croft and R. M. Siegel, Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases, Nat. Rev. Rheumatol, vol.13, pp.217-233, 2017.

N. Cusson-hermance, S. Khurana, T. H. Lee, K. A. Fitzgerald, and M. A. Kelliher, Rip1 Mediates the Trif-dependent Toll-like Receptor 3-and 4-induced NF-?B Activation but Does Not Contribute to Interferon Regulatory Factor 3 Activation, J. Biol. Chem, vol.280, pp.36560-36566, 2005.

A. K. Daly, A. E. Rettie, D. M. Fowler, and J. O. Miners, Pharmacogenomics of CYP2C9: Functional and Clinical Considerations ?, J. Pers. Med, vol.8, 2017.

M. Del-giudice and S. W. Gangestad, Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters, Brain. Behav. Immun, vol.70, pp.61-75, 2018.

M. Deng, M. J. Scott, P. Loughran, G. Gibson, C. Sodhi et al., Lipopolysaccharide Clearance, Bacterial Clearance, and Systemic Inflammatory Responses Are Regulated by Cell Type-Specific Functions of TLR4 during Sepsis, J. Immunol. Author Choice, vol.190, pp.5152-5160, 2013.

T. Domoszlai, A. Martincuks, D. Fahrenkamp, H. Schmitz-van-de-leur, A. Kuster et al., Consequences of the disease-related L78R mutation for dimerization and activity of STAT3, J. Cell Sci, vol.127, pp.1899-1910, 2014.

Z. Dong, W. Tai, W. Lei, Y. Wang, Z. Li et al., IL-27 inhibits the TGF-?1-induced epithelial-mesenchymal transition in alveolar epithelial cells, BMC Cell Biol, vol.17, 2016.

B. Döring and E. Petzinger, Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism, Drug Metab. Rev, vol.46, pp.261-282, 2014.

A. Dunne, M. Ejdebäck, P. L. Ludidi, L. A. O'neill, and N. J. Gay, Structural Complementarity of Toll/Interleukin-1 Receptor Domains in Toll-like Receptors and the Adaptors Mal and MyD88, J. Biol. Chem, vol.278, pp.41443-41451, 2003.

T. E. Escher, A. J. Lui, E. S. Geanes, K. R. Walter, O. Tawfik et al., Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis, Mol. Cancer Res. molcanres, p.916, 2018.

R. Ferrao, H. Zhou, Y. Shan, Q. Li, D. E. Shaw et al., , p.4, 2014.

, Dimerization and Trans-autophosphorylation are Induced by Myddosome Assembly, Mol. Cell, vol.55, pp.891-903

G. Finazzi, V. De-stefano, and T. Barbui, Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018, Blood Cancer J, vol.8, 2018.

K. A. Fitzgerald, E. M. Palsson-mcdermott, A. G. Bowie, C. A. Jefferies, A. S. Mansell et al., Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction, Nature, vol.413, p.78, 2001.

K. A. Fitzgerald, S. M. Mcwhirter, K. L. Faia, D. C. Rowe, E. Latz et al., IKK? and TBK1 are essential components of the IRF3 signaling pathway, Nat. Immunol, vol.4, p.491, 2003.

R. M. Fleischmann, N. S. Damjanov, A. J. Kivitz, A. Legedza, T. Hoock et al., A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis, Arthritis Rheumatol. Hoboken NJ, vol.67, pp.334-343, 2015.

C. Gabay and I. Kushner, Acute-Phase Proteins and Other Systemic Responses to Inflammation, N. Engl. J. Med, vol.340, pp.448-454, 1999.

C. Garlanda, C. A. Dinarello, and A. Mantovani, The Interleukin-1 Family: Back to the Future, Immunity, vol.39, pp.1003-1018, 2013.

G. Giaccone, R. E. Sanborn, S. N. Waqar, A. Martinez-marti, S. Ponce et al., A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation, Clin. Lung Cancer, vol.19, pp.567-574, 2018.

F. Ginhoux, M. Greter, M. Leboeuf, S. Nandi, P. See et al., Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages, Science, vol.330, pp.841-845, 2010.

M. R. Green, M. D. Newton, and K. M. Fancher, Off-Target Effects of BCR-ABL and JAK2 Inhibitors, Am. J. Clin. Oncol, vol.39, pp.76-84, 2016.

M. Griesshammer, G. Saydam, F. Palandri, G. Benevolo, M. Egyed et al., Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial, Ann. Hematol, vol.97, pp.1591-1600, 2018.

M. Griesshammer, J. Kiladjian, and C. Besses, Thromboembolic events in polycythemia vera, Ann. Hematol, vol.98, pp.1071-1082, 2019.

Y. Gu, Y. Gu, W. Sun, W. Sun, S. Zhang et al., Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells, Int. J. Mol. Med, vol.38, pp.903-911, 2016.

B. Hagenbuch and B. Stieger, THE SLCO (FORMER SLC21) SUPERFAMILY OF TRANSPORTERS, Mol. Aspects Med, vol.34, pp.396-412, 2013.

M. Haji-abdolvahab, M. R. Mofrad, and H. Schellekens, Chapter Eight -Interferon Beta: From Molecular Level to Therapeutic Effects, In International Review of Cell and Molecular Biology, pp.343-372, 2016.

J. E. Harris, M. Rashighi, N. Nguyen, A. Jabbari, G. Ulerio et al., Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata, J. Am. Acad. Dermatol, vol.74, pp.370-371, 2016.

C. Harrison, J. Kiladjian, H. K. Al-ali, H. Gisslinger, R. Waltzman et al., JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, N. Engl. J. Med, vol.366, pp.787-798, 2012.

C. N. Harrison, A. M. Vannucchi, J. Kiladjian, H. K. Al-ali, H. Gisslinger et al., Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis, Leukemia, vol.30, pp.1701-1707, 2016.

C. N. Harrison, A. J. Mead, A. Panchal, S. Fox, C. Yap et al., Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial, 2017.

G. Hartmann, H. Kim, and M. Piquette-miller, Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice, Int. Immunopharmacol, vol.1, pp.189-199, 2001.

S. H. Hazem, M. E. Shaker, S. A. Ashamallah, and T. M. Ibrahim, The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms, Chem. Biol. Interact, vol.220, pp.116-127, 2014.

A. Heine, S. A. Held, S. N. Daecke, S. Wallner, S. P. Yajnanarayana et al., The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, vol.122, pp.1192-1202, 2013.

S. Hermouet, A. Godard, D. Pineau, I. Corre, S. Raher et al., , 2002.

A. Production and . Interleukin, IL)-11 AND IL-8 IN POLYCYTHAEMIA VERA, Cytokine, vol.20, pp.178-183

S. Hermouet, E. Bigot-corbel, and B. Gardie, Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01402440

B. S. Hijmans, A. Grefhorst, M. H. Oosterveer, and A. K. Groen, Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences, Biochimie, vol.96, pp.121-129, 2014.

G. Hoeffel, Y. Wang, M. Greter, P. See, P. Teo et al., Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages, J. Exp. Med, vol.209, pp.1167-1181, 2012.

T. Horng, G. M. Barton, and R. Medzhitov, TIRAP: an adapter molecule in the Toll signaling pathway, Nat. Immunol, vol.2, p.835, 2001.

Y. Hu, Y. Hong, Y. Xu, P. Liu, D. Guo et al., Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC, Apoptosis Int. J. Program. Cell Death, vol.19, pp.1627-1636, 2014.

C. A. Hunter and S. A. Jones, IL-6 as a keystone cytokine in health and disease, Nat. Immunol, vol.16, pp.448-457, 2015.

H. Hurwitz, E. Van-cutsem, J. Bendell, M. Hidalgo, C. Li et al., Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies, Invest. New Drugs, vol.36, pp.683-695, 2018.

H. I. Hurwitz, N. Uppal, S. A. Wagner, J. C. Bendell, J. T. Beck et al., Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed, J. Clin. Oncol, vol.33, pp.4039-4047, 2015.

K. G. Hussaarts, G. D. Veerman, F. G. Jansman, T. Van-gelder, R. H. Mathijssen et al., Clinically relevant drug interactions with multikinase inhibitors: a review, Ther. Adv. Med. Oncol, vol.11, 2019.

M. Jagasia, R. Zeiser, M. Arbushites, P. Delaite, B. Gadbaw et al., , 2018.

, Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials, Immunotherapy, vol.10, pp.391-402

C. A. Janeway, Pillars Article: Approaching the Asymptote? Evolution and Revolution in Immunology, Cold Spring Harb Symp Quant Biol, vol.54, pp.4475-4487, 1989.

A. Jetter and G. A. Kullak-ublick, Drugs and hepatic transporters: A review, Pharmacol. Res, 2019.

X. Jiang, Y. Zhuang, Z. Xu, W. Wang, and H. Zhou, Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6, AAPS J, vol.18, pp.767-776, 2016.

E. Jirillo, D. Caccavo, T. Magrone, E. Piccigallo, L. Amati et al., The role of the liver in the response to LPS: experimental and clinical findings, J. Endotoxin Res, vol.8, pp.319-327, 2002.

D. E. Johnson, R. A. O'keefe, and J. R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol, vol.15, pp.234-248, 2018.

D. Joshipura, A. Alomran, P. Zancanaro, and D. Rosmarin, Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B, J. Am. Acad. Dermatol, vol.78, pp.1205-1207, 2018.

R. Jover, R. Bort, M. J. Gómez-lechón, and J. V. Castell, Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved, FASEB J, vol.16, pp.1799-1801, 2002.

E. Kaffe, R. Fiorotto, F. Pellegrino, V. Mariotti, M. Amenduni et al., ?-catenin and IL-1? dependent CXCL10 production drives progression of disease in a mouse model of Congenital Hepatic Fibrosis, Hepatol. Baltim. Md, vol.67, pp.1903-1919, 2018.

J. C. Kagan and R. Medzhitov, Phosphoinositide-Mediated Adaptor Recruitment Controls Toll-like Receptor Signaling, Cell, vol.125, pp.943-955, 2006.

J. C. Kagan, T. Su, T. Horng, A. Chow, S. Akira et al., TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-?, Nat. Immunol, vol.9, pp.361-368, 2008.

P. Kagan, M. Sultan, I. Tachlytski, M. Safran, and Z. Ben-ari, Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation, PLoS ONE, vol.12, 2017.

A. Kanayama, R. B. Seth, L. Sun, C. Ea, M. Hong et al., TAB2 and TAB3 Activate the NF-?B Pathway through Binding to Polyubiquitin Chains, Mol. Cell, vol.15, pp.535-548, 2004.

S. Kaur, A. Sassano, B. Dolniak, S. Joshi, B. Majchrzak-kita et al., Role of the Akt pathway in mRNA translation of interferonstimulated genes, Proc. Natl. Acad. Sci. U. S. A, vol.105, pp.4808-4813, 2008.

T. Kawai, A. , and S. , The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol, vol.11, pp.373-384, 2010.

C. Keohane, D. P. Mclornan, K. Sanchez, C. Connor, D. Radia et al., The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms, Haematologica, vol.100, pp.348-350, 2015.

J. W. Kim, J. Gautam, J. E. Kim, J. Kim, and K. W. Kang, Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor, Oncol. Lett, vol.17, pp.3981-3989, 2019.

S. Kim, A. J. Östör, and M. K. Nisar, Interleukin-6 and cytochrome-P450, reason for concern?, Rheumatol. Int, vol.32, pp.2601-2604, 2012.

M. Kleppe, M. H. Spitzer, S. Li, C. E. Hill, L. Dong et al., Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis, Cell Stem Cell, vol.21, pp.489-501, 2017.

H. Koepsell, The SLC22 family with transporters of organic cations, anions and zwitterions, Mol. Aspects Med, vol.34, pp.413-435, 2013.

H. M. Komar, G. Serpa, C. Kerscher, E. Schwoegl, T. A. Mace et al., Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo, 2017.

N. Koonrungsesomboon, R. Khatsri, P. Wongchompoo, and S. Teekachunhatean, The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis, Pharmacogenomics J, vol.18, p.760, 2018.

F. Kramer, J. Torzewski, J. Kamenz, K. Veit, V. Hombach et al., Interleukin-1? stimulates acute phase response and C-reactive protein synthesis by inducing an NF?B-and C/EBP?-dependent autocrine interleukin-6 loop, Mol. Immunol, vol.45, pp.2678-2689, 2008.

J. K. Lamba, Y. S. Lin, E. G. Schuetz, and K. E. Thummel, Genetic contribution to variable human CYP3A-mediated metabolism, Adv. Drug Deliv. Rev, vol.54, pp.1271-1294, 2002.

E. B. Lee, N. Daskalakis, C. Xu, A. Paccaly, B. Miller et al., Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis, Clin. Pharmacokinet, vol.56, pp.607-615, 2017.

Y. Lee, Y. Kim, Y. S. Jung, K. Kim, D. Kim et al., Hepatocyte toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression, Exp. Mol. Med, vol.49, p.408, 2017.

D. E. Levy and J. E. Darnell, STATs: transcriptional control and biological impact, Nat. Rev. Mol. Cell Biol, vol.3, p.651, 2002.

Q. Li and Y. Shu, Role of solute carriers in response to anticancer drugs, Mol. Cell. Ther, vol.2, 2014.

W. Li, H. Yang, X. Li, L. Han, N. Xu et al., Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer, Oncol. Rep, vol.41, pp.437-446, 2019.

S. T. Lim, Y. W. Jeon, H. Gwak, S. Y. Kim, and Y. J. Suh, Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells, Mol. Med. Rep, vol.17, pp.5581-5588, 2018.

S. Lin, Y. Lo, and H. Wu, Helical assembly in the MyD88:IRAK4:IRAK2 complex in TLR/IL-1R signaling, vol.465, pp.885-890, 2010.

D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M. Blum et al., LS104, a non-ATP-competitive smallmolecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells, Mol. Cancer Ther, vol.7, pp.1176-1184, 2008.

S. Liu, D. J. Gallo, A. M. Green, D. L. Williams, X. Gong et al., Role of Toll-Like Receptors in Changes in Gene Expression and NF-?B Activation in Mouse Hepatocytes Stimulated with Lipopolysaccharide, Infect. Immun, vol.70, pp.3433-3442, 2002.


F. Lussana and A. Rambaldi, Inflammation and myeloproliferative neoplasms, J. Autoimmun, vol.85, pp.58-63, 2017.

J. Mackay-wiggan, A. Jabbari, N. Nguyen, J. E. Cerise, C. Clark et al., Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata, JCI Insight, vol.1, 2016.

P. Mallick, G. Taneja, B. Moorthy, and R. Ghose, Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: Implications for biologics-small molecule drug interactions, Expert Opin. Drug Metab. Toxicol, vol.13, pp.605-616, 2017.

D. Mannina and N. Kröger, Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects, Drugs, 2019.

L. Marnell, C. Mold, D. Clos, and T. W. , C-reactive protein: Ligands, receptors and role in inflammation, Clin. Immunol, vol.117, pp.104-111, 2005.

J. Mascarenhas, R. Hoffman, M. Talpaz, A. T. Gerds, B. Stein et al., Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis, 2018.

S. Maschalidi, F. E. Sepulveda, A. Garrigue, A. Fischer, G. Basile et al., Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice, Blood, vol.128, pp.60-71, 2016.

M. Matsuda, S. Tsurusaki, N. Miyata, E. Saijou, H. Okochi et al.,

, Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice

J. D. Mcfadyen, J. Kiefer, D. Braig, J. Loseff-silver, L. A. Potempa et al., Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes, Front. Immunol, vol.9, 2018.

A. J. Mead, D. Milojkovic, S. Knapper, M. Garg, J. Chacko et al., Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial, Br. J. Haematol, vol.170, pp.29-39, 2015.

R. Medzhitov, P. Preston-hurlburt, and C. A. Janeway, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, vol.388, p.394, 1997.

C. Mertens, M. Zhong, R. Krishnaraj, W. Zou, X. Chen et al., Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain, Genes Dev, vol.20, pp.3372-3381, 2006.

R. Mesa, A. M. Vannucchi, A. Yacoub, P. Zachee, M. Garg et al., The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF), Br. J. Haematol, vol.176, pp.76-85, 2017.

L. Miele, V. Valenza, G. L. Torre, M. Montalto, G. Cammarota et al., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease, Hepatology, vol.49, pp.1877-1887, 2009.

M. Mihlan, A. M. Blom, K. Kupreishvili, N. Lauer, K. Stelzner et al., Monomeric C-reactive protein modulates classic complement activation on necrotic cells, FASEB J, vol.25, pp.4198-4210, 2011.

J. Mohrherr, M. Haber, K. Breitenecker, P. Aigner, S. Moritsch et al., JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression, Int. J. Cancer, 2019.

C. Mold, W. Rodriguez, B. Rodic-polic, and T. W. Clos, C-Reactive Protein Mediates Protection from Lipopolysaccharide Through Interactions With Fc?R, J. Immunol, vol.169, pp.7019-7025, 2002.

E. T. Morgan, Regulation of Cytochrome P450 by Inflammatory Mediators: Why and How?, Drug Metab. Dispos, vol.29, pp.207-212, 2001.

E. T. Morgan, K. B. Goralski, M. Piquette-miller, K. W. Renton, G. R. Robertson et al., Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metab. Dispos, vol.36, pp.205-216, 2008.

D. M. Mosser and J. P. Edwards, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol, vol.8, pp.958-969, 2008.

A. R. Mridha, A. Wree, A. A. Robertson, M. M. Yeh, C. D. Johnson et al., NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice, J. Hepatol, vol.66, pp.1037-1046, 2017.

R. Muller, JAK inhibitors in 2019, synthetic review in 10 points, Eur. J. Intern. Med, 2019.

P. J. Murray, Macrophage Polarization, Annu. Rev. Physiol, vol.79, pp.541-566, 2017.

K. Nakamura, Y. Kawato, Y. Kaneko, K. Hanaoka, K. Kubo et al., Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model, Transpl. Immunol, 2017.

D. Neculai, A. M. Neculai, S. Verrier, K. Straub, K. Klumpp et al., Structure of the Unphosphorylated STAT5a Dimer, J. Biol. Chem, vol.280, pp.40782-40787, 2005.

T. Neumann, L. Schneidewind, M. Weigel, A. Plis, R. Vaizian et al., Ruxolitinib for Therapy of Graft-versus-Host Disease, 2019.

D. Ofengeim and J. Yuan, Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death, Nat. Rev. Mol. Cell Biol, vol.14, pp.727-736, 2013.

A. B. Oliveira, . De, M. Alpalhão, P. Filipe, M. et al., The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review, Dermatol. Ther, vol.0, p.13053, 2019.

J. O'shaughnessy, A. Demichele, C. X. Ma, P. Richards, D. A. Yardley et al., A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation, Breast Cancer Res. Treat, vol.170, pp.547-557, 2018.

K. E. Panteli, E. C. Hatzimichael, P. K. Bouranta, A. Katsaraki, K. Seferiadis et al., Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases, Br. J. Haematol, vol.130, pp.709-715, 2005.

T. Papayannopoulou, B. Nakamoto, T. Yokochi, A. Chait, and R. Kannagi, Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA, Blood, vol.62, pp.832-845, 1983.

K. Papp, D. Pariser, M. Catlin, G. Wierz, G. Ball et al., A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis, Br. J. Dermatol, vol.173, pp.767-776, 2015.

S. Parampalli-yajnanarayana, T. Stübig, I. Cornez, H. Alchalby, K. Schönberg et al., JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms, Br. J. Haematol, vol.169, pp.824-833, 2015.

J. S. Park, M. H. Hong, Y. J. Chun, H. R. Kim, and B. C. Cho, A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs, Lung Cancer Amst. Neth, vol.134, pp.46-51, 2019.

F. Passamonti, M. Griesshammer, F. Palandri, M. Egyed, G. Benevolo et al., Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study, Lancet Oncol, vol.18, pp.88-99, 2017.

M. R. Patel, A. Dash, B. A. Jacobson, Y. Ji, D. Baumann et al.,

, JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models, Cancer Gene Ther

M. B. Pepys and G. M. Hirschfield, C-reactive protein: a critical update, J. Clin. Invest, vol.111, pp.1805-1812, 2003.

K. Phan and D. F. Sebaratnam, JAK inhibitors for alopecia areata: a systematic review and meta-analysis, J. Eur. Acad. Dermatol. Venereol. JEADV, 2019.

L. Pieri, C. Paoli, U. Arena, F. Marra, F. Mori et al., Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms, Am. J. Hematol, vol.92, pp.187-195, 2017.

L. C. Platanias, Mechanisms of type-I-and type-II-interferon-mediated signalling, Nat. Rev. Immunol, vol.5, p.375, 2005.

A. Poltorak, X. He, I. Smirnova, M. Liu, C. V. Huffel et al., Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene, Science, vol.282, pp.2085-2088, 1998.

A. L. Pranada, S. Metz, A. Herrmann, P. C. Heinrich, and G. Müller-newen, Real Time Analysis of STAT3 Nucleocytoplasmic Shuttling, J. Biol. Chem, vol.279, pp.15114-15123, 2004.

N. Punwani, T. Burn, P. Scherle, R. Flores, J. Shi et al., Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor, Br. J. Dermatol, vol.173, pp.989-997, 2015.

A. Quintás-cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li et al., Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood, vol.115, pp.3109-3117, 2010.

N. C. Reich, STATs get their move on, JAK-STAT, vol.2, 2013.

K. Ren and R. Torres, Role of interleukin-1? during pain and inflammation, Brain Res. Rev, vol.60, pp.57-64, 2009.

R. Paul and M. , Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention, Circulation, vol.107, pp.363-369, 2003.

S. Rose-john, The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation, Clin. Pharmacol. Ther, vol.102, pp.591-598, 2017.

B. Rothstein, D. Joshipura, A. Saraiya, R. Abdat, H. Ashkar et al., Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib, J. Am. Acad. Dermatol, vol.76, pp.1054-1060, 2017.

D. C. Rowe, A. F. Mcgettrick, E. Latz, B. G. Monks, N. J. Gay et al., The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction, Proc. Natl. Acad. Sci. U. S. A, vol.103, pp.6299-6304, 2006.

K. Rubin, A. Janefeldt, L. Andersson, Z. Berke, K. Grime et al., , 2015.

, HepaRG Cells as Human-Relevant In Vitro Model to Study the Effects of Inflammatory Stimuli on Cytochrome P450 Isoenzymes, Drug Metab. Dispos, vol.43, pp.119-125

J. Rudolph, A. Heine, T. Quast, W. Kolanus, J. Trebicka et al., , 2016.

, The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK, Leukemia, vol.30, pp.2119-2123

B. Samuelson, S. Vesely, C. Chai-adisaksopha, B. Scott, M. Crowther et al., The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis, Blood Coagul. Fibrinolysis, vol.27, pp.648-652, 2016.

J. Scheller, A. Chalaris, D. Schmidt-arras, R. , and S. , The pro-and antiinflammatory properties of the cytokine interleukin-6, Biochim. Biophys. Acta BBA -Mol. Cell Res, vol.1813, pp.878-888, 2011.

G. Schett, Physiological effects of modulating the interleukin-6 axis, Rheumatology, vol.57, pp.43-50, 2018.

C. Schmitt, B. Kuhn, X. Zhang, A. J. Kivitz, and S. Grange, Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis, Clin. Pharmacol. Ther, vol.89, pp.735-740, 2011.

K. Schönberg, J. Rudolph, M. Vonnahme, S. P. Yajnanarayana, I. Cornez et al., JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Res, vol.75, pp.2187-2199, 2015.

J. Seo, M. W. Kim, K. Bae, S. C. Lee, J. Song et al., The roles of ubiquitination in extrinsic cell death pathways and its implications for therapeutics, Biochem. Pharmacol, vol.162, pp.21-40, 2019.

M. E. Shaker, S. H. Hazem, and S. A. Ashamallah, Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity, Food Chem. Toxicol, vol.96, pp.290-301, 2016.

A. Shapouri-moghaddam, S. Mohammadian, H. Vazini, M. Taghadosi, S. Esmaeili et al., Macrophage plasticity, polarization, and function in health and disease, J. Cell. Physiol, vol.233, pp.6425-6440, 2018.

T. Sharifnia, J. Antoun, T. G. Verriere, G. Suarez, J. Wattacheril et al., Hepatic TLR4 signaling in obese NAFLD, Am. J. Physiol. -Gastrointest. Liver Physiol, vol.309, pp.270-278, 2015.

J. Shi and S. Sun, Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor ?B and Mitogen-Activated Protein Kinase Pathways, Front. Immunol, vol.9, 2018.

J. G. Shi, X. Chen, R. F. Mcgee, R. R. Landman, T. Emm et al., The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers, J. Clin. Pharmacol, vol.51, pp.1644-1654, 2011.

R. Shimazu, S. Akashi, H. Ogata, Y. Nagai, K. Fukudome et al.,

, MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4, J. Exp. Med, vol.189, pp.1777-1782

K. Shuai and B. Liu, Regulation of JAK-STAT signalling in the immune system, Nat. Rev. Immunol, vol.3, pp.900-911, 2003.

J. E. Sims and D. E. Smith, The IL-1 family: regulators of immunity, Nat. Rev. Immunol, vol.10, pp.89-102, 2010.

J. S. Smolen, M. M. Schoels, N. Nishimoto, F. C. Breedveld, G. R. Burmester et al., Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, Ann. Rheum. Dis, vol.72, pp.482-492, 2013.

N. R. Sproston and J. J. Ashworth, Role of C-Reactive Protein at Sites of Inflammation and Infection, Front. Immunol, vol.9, 2018.

J. Sridhar, N. Goyal, J. Liu, and M. Foroozesh, Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date, Mol. J. Synth. Chem. Nat. Prod. Chem, vol.22, 2017.

S. Stivala, T. Codilupi, S. Brkic, A. Baerenwaldt, N. Ghosh et al., Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms, J. Clin. Invest, vol.130, pp.1596-1611, 2019.

D. G. Stover, C. R. Gil-del-alcazar, J. Brock, H. Guo, B. Overmoyer et al., Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer, NPJ Breast Cancer, vol.4, 2018.

G. Szabo, S. Bala, J. Petrasek, and A. Gattu, Gut-Liver Axis and Sensing Microbes, Dig. Dis. Basel Switz, vol.28, pp.737-744, 2011.

T. Tanaka and T. Kishimoto, The Biology and Medical Implications of Interleukin-6, Cancer Immunol. Res, vol.2, pp.288-294, 2014.

P. Tang, M. Hung, and J. Klostergaard, Human pro-Tumor Necrosis Factor Is a Homotrimer, Biochemistry, vol.35, pp.8216-8225, 1996.

A. Tefferi, R. Vaidya, D. Caramazza, C. Finke, T. Lasho et al., , 2011.

, Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study, J. Clin. Oncol, vol.29, pp.1356-1363

J. Telliez, Janus Kinase Inhibitors, Encyclopedia of Inflammatory Diseases, M. Parnham, pp.1-5, 2016.

, Membrane transporters in drug development, The International Transporter Consortium, vol.9, pp.215-236, 2010.

P. S. Tobias, K. Soldau, and R. J. Ulevitch, Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum, J. Exp. Med, vol.164, pp.777-793, 1986.

J. Trial, L. A. Potempa, and M. L. Entman, The role of C-reactive protein in innate and acquired inflammation: new perspectives, Inflamm. Cell Signal, vol.3, 2016.

R. Vaidya, N. Gangat, T. Jimma, C. M. Finke, T. L. Lasho et al., Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis, Am. J. Hematol, vol.87, pp.1003-1005, 2012.

A. M. Vannucchi, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N. Engl. J. Med, vol.372, pp.1670-1671, 2015.

M. L. Vee, V. Lecureur, B. Stieger, and O. Fardel, Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-? or Interleukin-6, Drug Metab. Dispos, vol.37, pp.685-693, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00673249

S. Verma and E. T. Yeh, C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation, Am. J. Physiol. Regul. Integr. Comp. Physiol, vol.285, pp.1257-1258, 2003.

S. Verstovsek, H. Kantarjian, R. A. Mesa, A. D. Pardanani, J. Cortes-franco et al., Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, N. Engl. J. Med, vol.363, pp.1117-1127, 2010.

S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta et al., A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, N. Engl. J. Med, vol.366, pp.799-807, 2012.

S. Verstovsek, A. M. Vannucchi, M. Griesshammer, T. Masszi, S. Durrant et al., Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial, Haematologica, vol.101, pp.821-829, 2016.

S. Verstovsek, R. A. Mesa, J. Gotlib, V. Gupta, J. F. Dipersio et al., Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebocontrolled, phase 3 COMFORT-I trial, J. Hematol. Oncol.J Hematol Oncol, vol.10, 2017.

M. G. Vicent, B. Molina, J. G. Pablo, . De, A. Castillo et al., Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results, Am. J. Hematol, vol.94, pp.319-326, 2019.

A. Visintin, A. Mazzoni, J. A. Spitzer, and D. M. Segal, Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4, Proc. Natl. Acad. Sci. U. S. A, vol.98, p.12156, 2001.

C. Wang, L. Deng, M. Hong, G. R. Akkaraju, J. Inoue et al., TAK1 is a ubiquitin-dependent kinase of MKK and IKK, Nature, vol.412, p.346, 2001.

N. A. Weerd, . De, S. A. Samarajiwa, and P. J. Hertzog, Type I Interferon Receptors: Biochemistry and Biological Functions, J. Biol. Chem, vol.282, 2007.

S. D. Wright, P. S. Tobias, R. J. Ulevitch, and R. A. Ramos, Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages, J. Exp. Med, vol.170, pp.1231-1241, 1989.

S. D. Wright, R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison, CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein, Science, vol.249, pp.1431-1433, 1990.

L. Yu, L. Wang, C. , and S. , Endogenous toll-like receptor ligands and their biological significance, J. Cell. Mol. Med, vol.14, pp.2592-2603, 2010.

U. M. Zanger and M. Schwab, Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacol. Ther, vol.138, pp.103-141, 2013.

R. Zeiser, A. Burchert, C. Lengerke, M. Verbeek, K. Maas-bauer et al., Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey, Leukemia, vol.29, pp.2062-2068, 2015.

D. Zhang, M. Sun, D. Samols, and I. Kushner, STAT3 Participates in Transcriptional Activation of the C-reactive Protein Gene by Interleukin-6, J. Biol. Chem, vol.271, pp.9503-9509, 1996.

Y. Zhang, R. Liang, C. Chen, T. Mallano, C. Dees et al., JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment, Ann. Rheum. Dis, vol.76, pp.1467-1475, 2017.

T. Zhou, S. Georgeon, R. Moser, D. J. Moore, A. Caflisch et al., , 2014.

, Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348), Leukemia, vol.28, pp.404-407

Y. Zhuang, D. E. De-vries, Z. Xu, S. J. Marciniak, D. Chen et al., Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach, J. Clin. Pharmacol, vol.55, pp.1386-1394, 2015.

M. -james, V. Lecureur, and O. Fardel, The JAK1/2 inhibitor ruxolitinib represses LPS-mediated expression of acute phase proteins in cultured human hepatocytes, Activités scientifiques et enseignement Publications 1 -Febvre, 2019.

, Inflammation Research

. -«-prévention, Risque incendie, biologique et chimique » -09 Novembre 2016 -Rennes 4 -« Manipulation des sources radioactives non scellées » -09 Novembre 2016 -Rennes Enseignement : Missions d'enseignement

, UE Histologie -IUT 1ere année -Université Clermont Auvergne -27h TP -Semestre 2 2018 2 -UE Microenvironnement Cellulaire Normal et Pathologique -Master 2 Biologie Moléculaire et Cellulaire -Université de Rennes 1 -1h30 CM, p.1, 2017.

-. Cellulaire, apoptose et vieillissement -Licence 3 Biologie Cellulaire, Génétique, Microbiologie, Physiologie animale -Université de Rennes 1 -28h TP (dont 22h en anglais) -Semestre, pp.24-25, 2016.

, -UE Organisation fonctionnelle de la cellule -Licence 2 Sciences Moléculaires et Cellulaires -Université de Rennes 1 -12h TP -Semestre, 2017.

, -Présentation des résultats au cours de réunions de travail dans le cadre du projet HII-GO -Cancéropôle Grand-Ouest -Nantes -31 Mars 2016 et 8 Juin 2017 + 2 Visioconférences, 2016.

, 2 -Participation aux Journées Portes Ouvertes de l'Université de Rennes 1 en 2016 et 2017 -Organisation des visites des salles de TP